EE151 APALUTAMIDE (APA) AS FIRST OPTION TO METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) REPRESENTS COST-EFFECTIVE TREATMENT SEQUENCES TO HEALTH SYSTEMS
Value in Health · 2026-06 · 29 (6) · S91-S92
DOI: 10.1016/j.jval.2026.03.446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Lucas Silva und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Silva, L., Nogueira, T., Pando, L., Vidal, G., Montone, B., & Macedo, M. (2026). EE151 APALUTAMIDE (APA) AS FIRST OPTION TO METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) REPRESENTS COST-EFFECTIVE TREATMENT SEQUENCES TO HEALTH SYSTEMS. Value in Health, 29(6), S91-S92. https://doi.org/10.1016/j.jval.2026.03.446
Vancouver
Silva L, Nogueira T, Pando L, Vidal G, Montone B, Macedo M. EE151 APALUTAMIDE (APA) AS FIRST OPTION TO METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) REPRESENTS COST-EFFECTIVE TREATMENT SEQUENCES TO HEALTH SYSTEMS. Value in Health. 2026;29(6):S91-S92. doi:10.1016/j.jval.2026.03.446
BibTeX
@article{Silva2026,
author = {Silva, Lucas and Nogueira, Thiago and Pando, Larissa and Vidal, Graziela and Montone, Bianca and Macedo, Mariana},
title = {EE151 APALUTAMIDE (APA) AS FIRST OPTION TO METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) REPRESENTS COST-EFFECTIVE TREATMENT SEQUENCES TO HEALTH SYSTEMS},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S91--S92},
doi = {10.1016/j.jval.2026.03.446}
}
EUVIMED